1.Age-Related Changes in the Prevalence of Osteoporosis according to Gender and Skeletal Site: The Korea National Health and Nutrition Examination Survey 2008-2010.
Jongseok LEE ; Sungwha LEE ; Sungok JANG ; Ohk Hyun RYU
Endocrinology and Metabolism 2013;28(3):180-191
BACKGROUND: The incidence of osteoporosis and its related fractures are expected to increase significantly in the rapidly aging Korean population. Reliable data on the prevalence of this disease is essential for treatment planning. However, sparse data on Korean patients is available. METHODS: We analyzed data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2008 to 2010. Bone mineral density (BMD) was measured at the femoral neck and lumbar spine using dual-energy X-ray absorptiometry. Osteopenia and osteoporosis were diagnosed according to the World Health Organization T-score criteria. We analyzed the BMD data of 17,208 people (men, 7,837; women, 9,368). RESULTS: The adjusted prevalence of osteoporosis was 7.8% in men versus 37.0% in women. No significant difference was observed in the prevalence of osteopenia between genders (men, 47.0%; women, 48.7%). The prevalence of osteoporosis in men in their 50s was 4.0%, in their 60s was 7.2%, in their 70s was 15.1%, and in their 80s was 26.7%. The figures in women were 15.2%, 36.5%, 62.7%, and 85.8%, respectively. The age group with the maximal BMD differed between genders. In the men, 20s had the highest value in all the skeletal sites. However, in the women, the maximal BMD in the femoral neck, lumbar spine, and the total hip was observed in their 20s, 30s, and 40s, respectively. The onset age of osteoporosis differed between genders. Osteoporosis in the femoral neck began at 55 years in the women and at 60 years in the men. CONCLUSION: The prevalence of osteoporosis in Korea was significantly high. In addition, the age-related changes in the prevalence of osteoporosis differed according to gender and skeletal site.
Absorptiometry, Photon
;
Age of Onset
;
Aging
;
Bone Density
;
Bone Diseases, Metabolic
;
Female
;
Femur Neck
;
Hip
;
Humans
;
Incidence
;
Korea
;
Male
;
Nutrition Surveys
;
Osteoporosis
;
Prevalence
;
Spine
;
World Health Organization
2.Management Status of Cardiovascular Disease Risk Factors for Dyslipidemia among Korean Adults.
Jongseok LEE ; Heejeong SON ; Ohk Hyun RYU
Yonsei Medical Journal 2017;58(2):326-338
PURPOSE: Dyslipidemia, hypertension, and diabetes are well-established risk factors for cardiovascular disease (CVD). This study investigated the prevalence and management status of these factors for dyslipidemia among Korean adults aged 30 years old and older. MATERIALS AND METHODS: The prevalence and management status of dyslipidemia, hypertension, and diabetes were analyzed among 12229 subjects (≥30 years) participating in the Korea National Health and Nutrition Survey 2010–2012. Dyslipidemia was defined according to treatment criteria rather than diagnostic criteria in Korea. Therefore, hyper-low-density lipoprotein (LDL) cholesterolemia was defined if LDL cholesterol levels exceeded the appropriate risk-based threshold established by the National Cholesterol Education Program Adult Treatment Panel III. RESULTS: The age-standardized prevalence was highest for dyslipidemia (39.6%), followed by hypertension (32.8%) and diabetes (9.8%). The lowest patient awareness was found for dyslipidemia (27.9%). The treatment rate was 66.5% for diabetes and 57.3% for hypertension, but only 15.7% for dyslipidemia. The control rate among those undergoing treatment was highest for hypertension (64.2%), followed by dyslipidemia (59.2%) and diabetes (22.1%). The higher the risk levels of CVD were, the lower the control rate of dyslipidemia. CONCLUSION: While the prevalence of dyslipidemia was higher than hypertension and diabetes, awareness and treatment rates thereof were lower. Higher CVD-risk categories showed lower control rates of dyslipidemia. In order to improve awareness and control rates of dyslipidemia, diagnostic criteria should be reconciled with treatment targets based on cardiovascular risk in Korean populations.
Adult*
;
Cardiovascular Diseases*
;
Cholesterol
;
Cholesterol, LDL
;
Diabetes Mellitus
;
Dyslipidemias*
;
Education
;
Humans
;
Hypertension
;
Korea
;
Lipoproteins
;
Nutrition Surveys
;
Prevalence
;
Risk Factors*
3.Communication Strategies for Patients with Diabetes.
Journal of Korean Diabetes 2016;17(4):257-260
Communication with patients is a very important process in medical care to establish close relation (rapport) for diabetes management. Medical personnel have to communicate differently according to the characteristics, socioeconomic status, and family support available for each patient. We can use two different communication tools (verbal and non-verbal) to build rapport with patients. It is necessary to choose suitable language based on patient education level and background. We can reinforce patient' motivation regarding diabetes management by using positive messages (i.e., the benefits of diabetes management) or negative messages (i.e., the harmfulness of uncontrolled diabetes). We have to consider every patient as a human being, not just their disease. Understanding, careful listening, and empathy for diabetic patients will make rapport and lead to better diabetes management.
Diabetes Mellitus
;
Disease Management
;
Empathy
;
Humans
;
Motivation
;
Patient Education as Topic
;
Social Class
4.Approach to the Patient with Hypertension Accompanied by Hypokalemia.
Korean Journal of Medicine 2017;92(4):387-391
No abstract available.
Humans
;
Hypertension*
;
Hypokalemia*
5.Validation of the Friedewald formula for estimating low density lipoprotein cholesterol: the Korea National Health and Nutrition Examination Survey, 2009 to 2011
Jongseok LEE ; Sungok JANG ; Haemin JEONG ; Ohk-Hyun RYU
The Korean Journal of Internal Medicine 2020;35(1):150-159
Background/Aims:
The aim of this study is to compare Friedewald-estimated and directly measured low density lipoprotein cholesterol (LDL-C) values and assess the concordance in guideline risk classification between the two methods.
Methods:
The data were derived from the 2009 to 2011 Korea National Health and Nutrition Examination Survey. We included subjects with triglyceride (TG) levels < 400 mg/dL. Analysis was done for 6,454 subjects who had all lipid panels— total cholesterol, directly measured LDL-C, high density lipoprotein cholesterol (HDL-C), and TG.
Results:
The subjects ranged in age from 10 to 87 years old. The mean age was 41.5 ± 17.3 years. For subjects with TG < 400 mg/dL, overall concordance in guideline risk classification was 79.1%. The Friedewald formula tended to underestimate LDL-C more at higher TG or lower HDL-C levels. Especially, the percent of subjects who were misclassified into a lower risk category was 31% when TG were 200 to 299 mg/dL; and 45.6% when TG were 300 to 399 mg/dL. A greater underestimation of LDL-C occurred at higher TG and lower Friedewald-estimated LDL-C levels. Of subjects with a Friedewald-estimated LDL-C < 70 mg/dL, 55.4% had a directly measured LDL-C ≥ 70 mg/dL when TG were 200 to 399 mg/dL.
Conclusions
The Friedewald equation tends to underestimate LDL-C in highrisk subjects such as hypertriglyceridemia and hypo-HDL-cholesterolemia. For these individuals accurate assessment of LDL-C is crucial, and therefore additional evaluation is warranted.
6.Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes
Hyun-Woong CHO ; Wankyo CHUNG ; Shinje MOON ; Ohk-Hyun RYU ; Min Kyung KIM ; Jun Goo KANG
Diabetes & Metabolism Journal 2020;44(S1):e38-
Background:
This study aimed to assess the effects of sarcopenia and A Body Shape Index (ABSI) on cardiovascular disease (CVD) risk according to obesity phenotypes.
Methods:
We used data from the National Health and Nutrition Examination Survey 1999 to 2012. A total of 25,270 adults were included and classified into the following groups: metabolically healthy normal weight (MHNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese (MUO). Sarcopenia was defined as the appendicular skeletal mass index <7 kg/m2 in men and <5.5 kg/m2 in women. A multivariate logistic regression analysis was performed to evaluate the odds ratio (OR) of sarcopenia and ABSI for CVD events according to the obesity phenotype.
Results:
The MHNW participants with sarcopenia had higher risk for CVD than those without sarcopenia (OR, 2.69; 95% confidence interval [CI], 1.56 to 4.64). In the analysis with MHNW participants without sarcopenia as a reference, the participants with sarcopenia showed a higher OR for CVD than those without sarcopenia in both MHO (OR in participants without sarcopenia, 3.31; 95% CI, 1.94 to 5.64) (OR in participants with sarcopenia, 8.59; 95% CI, 2.63 to 28.04) and MUO participants (OR in participants without sarcopenia, 5.11; 95% CI, 3.21 to 8.15) (OR in participants with sarcopenia, 8.12; 95% CI, 4.04 to 16.32). Participants within the second and third tertiles of ABSI had higher ORs for CVDs than the counterpart of obesity phenotypes within the first tertile.
Conclusion
These results suggest that clinical approaches that consider muscle and body shape are required.
7.Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes
Hyun-Woong CHO ; Wankyo CHUNG ; Shinje MOON ; Ohk-Hyun RYU ; Min Kyung KIM ; Jun Goo KANG
Diabetes & Metabolism Journal 2021;45(2):209-218
This study aimed to assess the effects of sarcopenia and A Body Shape Index (ABSI) on cardiovascular disease (CVD) risk according to obesity phenotypes. We used data from the National Health and Nutrition Examination Survey 1999 to 2012. A total of 25,270 adults were included and classified into the following groups: metabolically healthy normal weight (MHNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese (MUO). Sarcopenia was defined as the appendicular skeletal mass index <7 kg/m2 in men and <5.5kg/m2 in women. A multivariate logistic regression analysis was performed to evaluate the odds ratio (OR) of sarcopenia and ABSI for CVD events according to the obesity phenotype. The MHNW participants with sarcopenia had higher risk for CVD than those without sarcopenia (OR, 2.69; 95% confidence interval [CI], 1.56 to 4.64). In the analysis with MHNW participants without sarcopenia as a reference, the participants with sarcopenia showed a higher OR for CVD than those without sarcopenia in both MHO (OR in participants without sarcopenia, 3.31; 95% CI, 1.94 to 5.64) (OR in participants with sarcopenia, 8.59; 95% CI, 2.63 to 28.04) and MUO participants (OR in participants without sarcopenia, 5.11; 95% CI, 3.21 to 8.15) (OR in participants with sarcopenia, 8.12; 95% CI, 4.04 to 16.32). Participants within the second and third tertiles of ABSI had higher ORs for CVDs than the counterpart of obesity phenotypes within the first tertile. These results suggest that clinical approaches that consider muscle and body shape are required.
8.Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes
Hyun-Woong CHO ; Wankyo CHUNG ; Shinje MOON ; Ohk-Hyun RYU ; Min Kyung KIM ; Jun Goo KANG
Diabetes & Metabolism Journal 2021;45(2):209-218
This study aimed to assess the effects of sarcopenia and A Body Shape Index (ABSI) on cardiovascular disease (CVD) risk according to obesity phenotypes. We used data from the National Health and Nutrition Examination Survey 1999 to 2012. A total of 25,270 adults were included and classified into the following groups: metabolically healthy normal weight (MHNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese (MUO). Sarcopenia was defined as the appendicular skeletal mass index <7 kg/m2 in men and <5.5kg/m2 in women. A multivariate logistic regression analysis was performed to evaluate the odds ratio (OR) of sarcopenia and ABSI for CVD events according to the obesity phenotype. The MHNW participants with sarcopenia had higher risk for CVD than those without sarcopenia (OR, 2.69; 95% confidence interval [CI], 1.56 to 4.64). In the analysis with MHNW participants without sarcopenia as a reference, the participants with sarcopenia showed a higher OR for CVD than those without sarcopenia in both MHO (OR in participants without sarcopenia, 3.31; 95% CI, 1.94 to 5.64) (OR in participants with sarcopenia, 8.59; 95% CI, 2.63 to 28.04) and MUO participants (OR in participants without sarcopenia, 5.11; 95% CI, 3.21 to 8.15) (OR in participants with sarcopenia, 8.12; 95% CI, 4.04 to 16.32). Participants within the second and third tertiles of ABSI had higher ORs for CVDs than the counterpart of obesity phenotypes within the first tertile. These results suggest that clinical approaches that consider muscle and body shape are required.
9.Sleep Disturbances and Glucoregulation in Patients with Type 2 Diabetes.
Eun Hee CHO ; Heyjean LEE ; Ohk Hyun RYU ; Moon Gi CHOI ; Sang Wook KIM
Journal of Korean Medical Science 2014;29(2):243-247
We investigated the frequency of sleep disturbances and the association between sleep disturbances and glucoregulation in type 2 diabetic patients. The frequency of sleep disturbances in 614 type 2 diabetic patients was investigated using validated sleep questionnaires. There were 381 male and 233 female patients. The mean age was 59.7 +/- 11.1 yr; the mean body mass index was 24.9 +/- 4.4 kg/m2; the mean HbA1c was 7.8% +/- 1.5%; and the mean duration of diabetes was 10.3 +/- 8.4 yr. The questionnaires revealed insomnia in 48.2% of the patients while 8.5% reported excessive daytime sleepiness. A total of 49% of the patients was poor sleepers, while 28.5% had depression. Multivariate logistic regression analysis showed that there was no significant association between HbA1c and other sleep disturbances, such as poor sleep, insomnia, and short duration of sleep. Sleep disturbances were very common in patients with type 2 diabetes mellitus, whereas there was no association between poor or short sleep and glucoregulation. Awareness and identifying sleep complaints in such patients are necessary to improve their quality of daily life.
Adult
;
Aged
;
Body Mass Index
;
Depression/epidemiology
;
Diabetes Mellitus, Type 2/complications/*diagnosis/drug therapy
;
Female
;
Hemoglobin A, Glycosylated/analysis
;
Humans
;
Hypoglycemic Agents/therapeutic use
;
Logistic Models
;
Male
;
Middle Aged
;
Quality of Life
;
Questionnaires
;
Sleep Disorders/*complications
;
Sleep Initiation and Maintenance Disorders/epidemiology
10.Characteristics of Korean Patients with Primary Adrenal Insufficiency: A Registry-Based Nationwide Survey in Korea.
A Ram HONG ; Ohk Hyun RYU ; Seong Yeon KIM ; Sang Wan KIM
Endocrinology and Metabolism 2017;32(4):466-474
BACKGROUND: Primary adrenal insufficiency (PAI) is a rare, potentially life-threatening condition. There are few Korean studies on PAI, and most have had small sample sizes. We aimed to examine the etiology, clinical characteristics, treatment, and mortality of PAI in Korean patients. METHODS: A nationwide, multicenter, registry-based survey was conducted to identify adults diagnosed with or treated for PAI at 30 secondary or tertiary care institutions in Korea between 2000 and 2014. RESULTS: A total of 269 patients with PAI were identified. The prevalence of PAI was 4.17 per million. The estimated incidence was 0.45 per million per year. The mean age at diagnosis was 49.0 years, and PAI was more prevalent in men. Adrenal tuberculosis was the most common cause of PAI in patients diagnosed before 2000; for those diagnosed thereafter, adrenal metastasis and tuberculosis were comparable leading causes. The etiology of PAI was not identified in 34.9% of cases. Of the patients receiving glucocorticoid replacement therapy, prednisolone was more frequently administered than hydrocortisone (69.4% vs. 26.5%, respectively), and only 27.1% of all patients received fludrocortisone. We observed an increased prevalence of metabolic disease and osteoporosis during the follow-up period (median, 60.2 months). The observed overall mortality and disease-specific mortality rates were 11.9% and 3.1%, respectively. CONCLUSION: The prevalence of PAI is significantly lower in Koreans than in reports from Western countries. The high frequency undetermined etiology in patients with PAI suggests the need to reveal accurate etiology of PAI in Korea.
Addison Disease*
;
Adult
;
Autoimmune Diseases
;
Diagnosis
;
Fludrocortisone
;
Follow-Up Studies
;
Glucocorticoids
;
Humans
;
Hydrocortisone
;
Incidence
;
Korea*
;
Male
;
Metabolic Diseases
;
Mortality
;
Neoplasm Metastasis
;
Osteoporosis
;
Prednisolone
;
Prevalence
;
Sample Size
;
Tertiary Healthcare
;
Tuberculosis